Isoquinolinequinone N-oxides as anticancer agents effective against drug resistant cell lines
dc.contributor.author | Kruschel, Ryan D. | |
dc.contributor.author | Buzid, Alyah | |
dc.contributor.author | Khandavilli, Udaya Bhaskara Rao | |
dc.contributor.author | Lawrence, Simon E. | |
dc.contributor.author | Glennon, Jeremy D. | |
dc.contributor.author | McCarthy, Florence O. | |
dc.contributor.funder | Irish Research Council | en |
dc.contributor.funder | European Cooperation in Science and Technology | en |
dc.date.accessioned | 2020-02-11T15:22:51Z | |
dc.date.available | 2020-02-11T15:22:51Z | |
dc.date.issued | 2019-12-18 | |
dc.date.updated | 2020-02-11T15:11:18Z | |
dc.description.abstract | The isoquinolinequinone (IQQ) pharmacophore is a privileged framework in known cytotoxic natural product families, caulibugulones and mansouramycins. Exploiting both families as a chemical starting point, we report on the structured development of an IQQ N-oxide anticancer framework which exhibits growth inhibition in the nM range across melanoma, ovarian and leukaemia cancer cell lines. A new lead compound (16, R6 = benzyl, R7 = H) exhibits nM GI50 values against 31/57 human tumour cell lines screened as part of the NCI60 panel and shows activity against doxorubicin resistant tumour cell lines. An electrochemical study highlights a correlation between electropositivity of the IQQ N-oxide framework and cytotoxicity. Adduct binding to sulfur based biological nucleophiles glutathione and cysteine was observed in vitro. This new framework possesses significant anticancer potential. | en |
dc.description.status | Peer reviewed | en |
dc.description.version | Accepted Version | en |
dc.format.mimetype | application/pdf | en |
dc.identifier.citation | Kruschel, R. D., Buzid, A., Khandavilli, U. B. R., Lawrence, S. E., Glennon, J. D. and McCarthy, F. O. (2020) 'Isoquinolinequinone N-oxides as anticancer agents effective against drug resistant cell lines', Organic & Biomolecular Chemistry, 18(3), pp. 557-568. doi: 10.1039/C9OB02441G | en |
dc.identifier.doi | 10.1039/C9OB02441G | en |
dc.identifier.endpage | 568 | en |
dc.identifier.issn | 1477-0520 | |
dc.identifier.issued | 3 | en |
dc.identifier.journaltitle | Organic & Biomolecular Chemistry | en |
dc.identifier.startpage | 557 | en |
dc.identifier.uri | https://hdl.handle.net/10468/9633 | |
dc.identifier.volume | 18 | en |
dc.language.iso | en | en |
dc.publisher | Royal Society of Chemistry | en |
dc.relation.project | European Cooperation in Science and Technology (COST Action CA15135) | en |
dc.relation.uri | https://pubs.rsc.org/en/content/articlehtml/2020/ob/c9ob02441g | |
dc.rights | https://pubs.rsc.org/en/content/articlelanding/2020/OB/C9OB02441G | en |
dc.subject | Lead compounds | en |
dc.subject | Amino acids | en |
dc.subject | Cell culture | en |
dc.subject | Cells | en |
dc.subject | Tumors | en |
dc.subject | Anti-cancer agents | en |
dc.subject | Anticancer potentials | en |
dc.subject | Cancer cell lines | en |
dc.subject | Electrochemical studies | en |
dc.subject | Growth inhibition | en |
dc.subject | Natural products | en |
dc.subject | Pharmacophores | en |
dc.subject | Resistant cells | en |
dc.title | Isoquinolinequinone N-oxides as anticancer agents effective against drug resistant cell lines | en |
dc.type | Article (peer-reviewed) | en |
Files
Original bundle
License bundle
1 - 1 of 1
Loading...
- Name:
- license.txt
- Size:
- 2.71 KB
- Format:
- Item-specific license agreed upon to submission
- Description: